Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.

Published version
Repository URI
https://www.repository.cam.ac.uk/handle/1810/278135
Repository DOI
https://doi.org/10.17863/CAM.25479
Files
Published version (889.09 KB)
Accepted version (183.35 KB)
Type
Article
Change log
Authors
Hiller, Louise 
Dunn, Janet A 
Loi, Shrushma 
Vallier, Anne-Laure 
Howe, Donna L 
Show 4 more
Description
Keywords
Humans, Breast Neoplasms, Receptor, erbB-2, Treatment Outcome, Chemotherapy, Adjuvant, Perception, Female, Cardiotoxicity, Surveys and Questionnaires, Trastuzumab, Antineoplastic Agents, Immunological
Journal Title
BMC cancer
Conference Name
Journal ISSN
1471-2407
1471-2407
Volume Title
18
Publisher
Publisher DOI
https://doi.org/10.1186/s12885-018-4307-8
Rights
Attribution 4.0 International Repository logo
Sponsorship
NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) (HTA/06/303/98)
Collections
Scholarly Works - Oncology